LCMT2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: LCMT2

NCBI ID: G9836

LCMT2

LCMT2: A Potential Drug Target and Biomarker for Various Diseases

LCMT2 (tRNA-yW synthesizing protein 4) is a protein that is expressed in various tissues of the body, including muscle, heart, and brain. It is a member of the LCMT2 gene family, which encodes a protein that plays a role in the synthesis of tRNA, a molecule that carries genetic information from the DNA to the ribosome during the process of gene expression.

LCMT2 is a unique protein that is expressed in humans, and its function is not well understood. However, research has suggested that it may be involved in a variety of cellular processes, including muscle growth and repair, heart function, and brain development and function.

One of the most promising aspects of LCMT2 is its potential as a drug target. LCMT2 has been shown to play a role in the regulation of muscle growth and repair, and several studies have suggested that inhibiting its function may be a effective way to treat a variety of muscle-related conditions, including muscle weakness, muscle wasting, and myopathies.

In addition to its potential as a drug target, LCMT2 has also been shown to be a potential biomarker for a variety of diseases. For example, some studies have suggested that LCMT2 may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

LCMT2 is also of interest as a potential therapeutic target for a variety of other diseases and conditions. For example, LCMT2 has been shown to be involved in the regulation of cellular signaling pathways that are involved in a variety of processes, including cell growth, apoptosis (programmed cell death), and inflammation.

In conclusion, LCMT2 is a protein that is of interest as a drug target and as a potential biomarker for a variety of diseases. Further research is needed to fully understand its function and potential therapeutic applications.

Protein Name: Leucine Carboxyl Methyltransferase 2

Functions: Probable S-adenosyl-L-methionine-dependent methyltransferase that acts as a component of the wybutosine biosynthesis pathway. Wybutosine is a hyper modified guanosine with a tricyclic base found at the 3'-position adjacent to the anticodon of eukaryotic phenylalanine tRNA (By similarity). May methylate the carboxyl group of leucine residues to form alpha-leucine ester residues

The "LCMT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCMT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets